Prospective Cohort Study of Palbociclib for Postmenopausal Metastatic Breast Cancer

Prospective Cohort Study of Palbociclib for Postmenopausal Metastatic Breast Cancer - Palbociclib Cohort Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035863

Enrollment

700

Registered

2019-02-20

Start date

2019-02-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postmenopausal patients with unresectable and metastatic hormone receptor-positive breast cancer,

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Postmenopausal patients with ER-positive

Exclusion criteria

Exclusion criteria: Patients who is not adopt endocrine therapy.

Design outcomes

Primary

Measure	Time frame
progression-free survival (PFS) in each treatment line.	—

Secondary

Measure	Time frame
1) overall survival, 2) clinical benefit rate (CBR) 3) AEs 4) patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) 5) PFS 6) CBR with the next treatment 7) AEs caused by the subsequent treatment, 8) PRO-CTCAE with the subsequent treatment 9) reasons for selecting the treatment.	—

Countries

Japan

Contacts

Public ContactTakashi Ishikawa

Tokyo Medical University Hospital Breast surgery

tsihik55@gmail.com03-3342-6111

Outcome results